Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
CC transcript
EXELIXIS, INC. (EXEL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/01/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
05/09/2023 8-K Quarterly results
Docs: "Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million -"
05/08/2023 8-K Quarterly results
04/13/2023 8-K Quarterly results
03/22/2023 8-K Other Events  Interactive Data
03/20/2023 8-K Quarterly results
02/07/2023 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 – Cabozantinib franchise achieves approximately $1.4 billion in preliminary U.S. net product revenues for full year 2022, including approximately $375 million for fourth quarter 2022 –"
12/15/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
09/02/2022 8-K Other Events  Interactive Data
08/09/2022 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
07/19/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/23/2022 8-K Other Events  Interactive Data
02/17/2022 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022 — Corporate priorities for 2022 include initial readout of up to three cabozantinib pivotal trials&#59; initiation of pivotal trial program for XL092&#59; expansion of clinical programs for XL092, XB002 and XL102&#59; and multiple new development candidates from small molecule and biologics programs"
12/17/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/02/2021 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
08/05/2021 8-K Quarterly results
Docs: "EXELIXIS ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE"
06/21/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/05/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
02/10/2021 8-K Quarterly results
02/05/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy